Procept, Sandoz Pharma Ltd. deal

The companies agreed to extend for a third year their agreement to identify small molecules that interfere with CD4 in triggering stimulation of the immune system associated with autoimmune disease and organ transplant rejection.

PRCT (Cambridge, Mass.) will receive $2.2 million for R&D. To date, Sandoz has paid $14 million in research and licensing fees involving PRCT's small molecule compounds. ...